Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 261-818-3 | CAS number: 59587-38-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute oral toxicity (OECD 420, fixed dose method): LD50 between 300 and 2000 mg/kg bw
Acute dermal toxicitity (OECD 402, acute dermal toxicity): The LD50 was determined to be higher than 2000 mg/kg bw
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
Additional information
Acute oral toxicity (OECD420)
The acute oral toxicity of the test substance was assessed according to the Fixed dose Method (OECD guideline 420) and GLP principles. In this study one female Wistar (RccHan®:WIST) rat was dosed with 300 mg/kg bw test substance by gavage. Since no toxicity was observed, an additional female was treated with 2000 mg/kg bw and subsequently, since no mortality occurred within 5 days, 4 additional females were treated at this dose. However, the first animal dosed at 2000 mg/kg bw and one female of the main study were found dead on study days 7 and 5, respectively. As a consequence, and seeing that the rest of the animals were showing the same clinical signs and a body weight loss between days 1 and 8, it was considered necessary to sacrifice them for welfare reasons. Therefore, it was necessary to administer another four animals at 300 mg/kg in order to complete de main study at this dose level. No deaths occurred in this dose group during the 14 -day observation period. In the animals treated at 2000 mg/kg bw piloerection and/or hunched posture were observed in all animals between day 4 and their sacrifice. The initially dosed female also showed decreased activity, hypothermia, abnormal gait, reduced body tone and pallor on day 7, just before the animal was found dead. In addition, a body weight loss of 13-23% was observed in all the animals in this dose group that survived until day 8 of study. Gross pathology revealed enlarged kidneys in all animals. Additionally, one of them showed stomach with reddish area in mucosa. No other macroscopic findings were recorded at necropsy. In the animals treated at 300 mg/kg bw, no clinical signs, effects on body weight or gross pathology observations were found. Therefore, under the conditions of the test, the acute oral LD50 for the test substance in rat was determined to be between 300 and 2000 mg/kg bw (Envigo 2017). Based on these results, the test substance is considered to be acutely harmful (category 4).
Acute dermal toxicity (OECD402)
The acute dermal toxicity of the test substance was assessed according to OECD guideline 402 and GLP principles. In this study, initially, two males and two females Sprague Dawley (Sprague Dawley®SD®) rats were treated by dermal route on a single occasion at 2000 mg/kg under semi-occlusive conditions. After 24 hours the test substance was removed with distilled water. As no mortality was observed, this dose was administered in the main study. For the main study, five males and five females were treated on a single occasion at 2000 mg/kg. The observation period was 14 days. All animals were examined for clinical signs in the first 30 minutes after dermal application and 1, 2, 3 and 5 hours after on day 1 and once daily during test days 2-15. Administration area was also examined before administration and once daily from day 2 until the end of study. Body weights were recorded on day 1 (prior to administration) and on days 8 and 15. All animals were necropsied and examined Macroscopically. All animals from the main study survived until the end of the observation period. It was determined that body weight were within the range commonly recorded in rats of this strain and age. No clinical signs, local alterations (in administration area) and macroscopic findings were observed during the course of the study.
Since no mortality was recorded after administration of the tested substance at the dose of 2000 mg/kg, the LD50 was found to be higher than the above-mentioned dose when administered by dermal route to rats (Envigo 2018)
Justification for classification or non-classification
Based on the available information, classification and labelling of the substance for acute oral toxicity as category 4 (H302, harmful if swallowed) is warranted in accordance with EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation No. 1272/2008 and its amendments. Classification and labelling for acute dermal toxicity is not warranted.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.